This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Epizyme Résultats passés
Passé contrôle des critères 0/6
Informations clés
-16.7%
Taux de croissance des bénéfices
-2.4%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | 24.4% |
Rendement des fonds propres | n/a |
Marge nette | -391.9% |
Dernière mise à jour des bénéfices | 30 Jun 2022 |
Mises à jour récentes des performances passées
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05Ventilation des recettes et des dépenses
Comment Epizyme gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 22 | 53 | -208 | 113 | 123 |
31 Mar 22 | 38 | -236 | 125 | 123 |
31 Dec 21 | 37 | -251 | 134 | 123 |
30 Sep 21 | 34 | -267 | 137 | 102 |
30 Jun 21 | 33 | -257 | 136 | 102 |
31 Mar 21 | 22 | -251 | 133 | 102 |
31 Dec 20 | 16 | -232 | 125 | 102 |
30 Sep 20 | 12 | -222 | 114 | 0 |
30 Jun 20 | 14 | -202 | 100 | 0 |
31 Mar 20 | 17 | -192 | 83 | 0 |
31 Dec 19 | 24 | -173 | 68 | 126 |
30 Sep 19 | 29 | -140 | 57 | 0 |
30 Jun 19 | 23 | -141 | 51 | 0 |
31 Mar 19 | 30 | -122 | 47 | 0 |
31 Dec 18 | 22 | -124 | 44 | 0 |
30 Sep 18 | 12 | -137 | 40 | 0 |
30 Jun 18 | 12 | -137 | 38 | 0 |
31 Mar 18 | 10 | -136 | 38 | 0 |
31 Dec 17 | 10 | -134 | 37 | 0 |
30 Sep 17 | 10 | -133 | 36 | 0 |
30 Jun 17 | 17 | -120 | 35 | 0 |
31 Mar 17 | 8 | -120 | 31 | 0 |
31 Dec 16 | 8 | -110 | 28 | 0 |
30 Sep 16 | 8 | -97 | 27 | 0 |
30 Jun 16 | 2 | -96 | 26 | 0 |
31 Mar 16 | 2 | -94 | 25 | 0 |
31 Dec 15 | 3 | -132 | 24 | 0 |
30 Sep 15 | 12 | -125 | 23 | 0 |
Des revenus de qualité: EPZM is currently unprofitable.
Augmentation de la marge bénéficiaire: EPZM is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: EPZM is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accélération de la croissance: Unable to compare EPZM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: EPZM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Rendement des fonds propres
ROE élevé: EPZM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.